Clinical significance of determining the hypermethylation of the RUNX3 gene promoter and its cohypermethylation with the BRCA1 gene for patients with breast cancer.
Zoia RossokhaLiliia FishchukOlga LobanovaViktoriia VershyhoraNataliia MedvedievaValeriy CheshukRoman VereshchakoSvitlana PodolskaNataliia GorovenkoPublished in: Journal of cancer research and clinical oncology (2023)
A significantly increased frequency of the hypermethylation of the RUNX3 gene promoter region and its cohypermethylation with the BRCA1 gene promoter region was found in tumor tissue and blood samples from patients with breast cancer, in contrast to the control group. The identified differences indicate the importance of further investigations of suppressor genes cohypermethylation in patients with breast cancer. Further large-scale studies are needed to find out whether the detected hypermethylation and cohypermethylation of the RUNX3 gene promoter region will have an impact on the treatment strategy in patients.